V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk, Russia
GRNTI 76.33 Гигиена и эпидемиология
GRNTI 76.03 Медико-биологические дисциплины
OKSO 31.06.2001 Клиническая медицина
OKSO 31.08.08 Радиология
OKSO 32.08.12 Эпидемиология
OKSO 14.04.02 Ядерные физика и технологии
BBK 534 Общая диагностика
BBK 51 Социальная гигиена и организация здравоохранения. Гигиена. Эпидемиология
TBK 5712 Медицинская биология. Гистология
TBK 5734 Медицинская радиология и рентгенология
TBK 6212 Радиоактивные элементы и изотопы. Радиохимия
TBK 5708 Гигиена и санитария. Эпидемиология. Медицинская экология
Results: To develop a method for reducing the frequency and severity of early radiation reactions in patients with cancer of the uterus or cervix. Material and methods: We analyzed the results of treatment of 60 patients with cancer of the uterus and cervix, patients received a postoperative course of external beam radiotherapy combined with the intramuscular administration of the Derinat® radioprotector (sodium deoxyribonucleate); in the second arm, they received a postoperative course of external beam radiotherapy and standard therapy in case of radiation cystitis. The assessment of radiation reactions severity was performed with the EORTC QLQ-C30 criteria, WBC count, IPSS scale, urine analysis and cystoscopic examination evaluated with the developed by us scale. Results: Evaluation of the quality of life in patients with cervical or uterine cancer at the final stage of treatment using the IPSS scale showed that in the arm of patients with sodium deoxyribonucleate, there was a 30.4 % (p> 0.05) decrease in the symptoms of urinary disorders. The use of the radioprotector sodium deoxyribonucleate also statistically significantly reduced the incidence of radiation cystitis by 73 %. According to cystoscopy, the total bladder injury score at the end of treatment was 147 % lower. The number of leukocytes in the urine analysis at the end of treatment was 116.3 % lower (p≤0.01) in those who received sodium deoxyribonucleate Conclusion: The data obtained indicate the radioprotective efficacy of sodium deoxyribonucleate and make it possible to recommend its intramuscular administration to patients with cancer of the uterus and cervix against the background of external beam radiation therapy to reduce the frequency and severity of acute radiation cystitis in patients with cancer of the uterus or cervical cancer receiving external beam radiation therapy.
radiation cystitis, uterine cancer, cervical cancer, sodium deoxyribonucleate
1. Sostoyanie onkologicheskoy pomoschi naseleniyu Rossii v 2019 godu / Pod red. Kaprina A.D., Starinskogo V.V., Shahzadovoy A.O. M.: MNIOI im. P.A. Gercena. 2020. 239 s.
2. Bouchard M., Nadeau S., Gingras L., Raymond P., Beaulieu F., Beaulieu L., Germain I. Clinical Outcome of Adjuvant Treatment of Endometrial Cancer Using Aperture-Based Intensity-Modulated Radiotherapy // International Journal of Radiation Oncology Biology Physics. 2008. V.71, No. 5. P. 1343–1350. DOI:10.1016/j.ijrobp.2007.12.004.
3. Shakespeare T.P., Lim K.H., Lee K.M., Back M.F., Mukherjee R., Lu J.D. Phase II Study of the American Brachytherapy Society Guidelines for the Use of High-Dose Rate Brachytherapy in the Treatment of Cervical Carcinoma: Is 45–50.4 Gy Radiochemotherapy Plus 31.8 Gy in Six Fractions High-Dose Rate Brachytherapy Tolerable? // Int. J. Gynecol. Cancer. 2006. V.16, No. 1. P. 277–282.
4. Yalman D., Arican A., Ozsaran Z., Celik O.K., Yurut V., Esassolak M., et al. Evaluation of Morbidity after External Radiotherapy and Intracavitary Brachytherapy in 771 Patients with Carcinoma of the Uterine Cervix or Endometrium // Eur. J. Gynecol. Oncol. 2002. V.23, No. 1. P. 58–62.
5. Coyne K.S., Sexton C.C., Irwin D.E., Kopp Z.S., Kelleher C.J., Milsom I. The Impact of Overactive Bladder, Incontinence and Other Lower Urinary Tract Symptoms on Quality of Life, Work Productivity, Sexuality and Emotional Well-Being in Men and Women: Results from the EPIC Study // BJU Int. 2008. V.101, No. 11. P.1388–1395.
6. Jereczek-Fossa B.A., Badzio A., Jassem J. Factors Determining Acute Normal Tissue Reactions During Postoperative Radiotherapy in Endometrial Cancer: Analysis of 317 Consecutive Cases // Radiother. Oncol. 2003. V.68, No. 1. P. 33–39.
7. Nordling J., Fall M., Hanno P. Global Concepts of Bladder Pain Syndrome (Interstitial Cystitis). World Journal of Urology. 2011. V.30, No. 4. P. 457–464. doi:10.1007/s00345-011-0785-x.
8. Pavlidakey P.G., MacLennan G.T. Radiation Cystitis. The Journal of Urology. 2009. V.182, No. 3. P. 1172–1173. doi:10.1016/ j.juro.2009.06.034.
9. Sycheva I.V., Pasov V.V., Kurpesheva A.K. Konservativnye metody lecheniya mestnyh luchevyh povrezhdeniy, sformirovavshihsya v rezul'tate sochetannoy luchevoy terapii i brahiterapii raka predstatel'noy zhelezy // Sibirskiy onkologicheskiy zhurnal. 2012. T. 53, № 5. S. 57-60.
10. Kulaev M.T., Al'myashev A.Z., Mel'caev G.G., Schukin S.A. Naruzhnoe primenenie Derinata v lechenii luchevyh yazv i zlokachestvennyh opuholey vidimyh lokalizaciy // Kreativnaya hirurgiya i onkologiya. 2009. № 1. S. 35-39.
11. Zukov R.A., Kozina Yu.V., Kozin V.A., Slepov E.V. Optimizaciya luchevoy terapii bol'nyh rakom predstatel'noy zhelezy // Sibirskoe medicinskoe obozrenie. 2018. № 2. S. 100-105. DOI: 10.20333/2500136-2018-2-100-105.
12. Minaev N.N., Ivanova M.N., Bugrimov D.Yu., Klimovich A.A. Klinicheskaya effektivnost' agonista toll-podobnogo receptora 9 pri reparacii posle petlevoy elektroekscizii sheyki matki // Zh. akush. i zhen. bolezn. 2016. № 5. S. 101-112. DOI: 10.17816/JOWD655101-112.
13. Filatov O.Yu., Kashaeva O.V., Bugrimov D.Yu., Klimovich A.A. Morfologicheskie principy immunologicheskogo deystviya DNK eukariot // Rossiyskiy immunologicheskiy zhurnal. 2013. T.7, № 16. S. 385-390.
14. Kaplina E.N. Derinat-otechestvennyy prirodnyy immunomodulyator // Uspehi sovremennogo estestvoznaniya. 2003. № 5. S. 63-64.
